// App-Quantinova.ai

AB0302 : RESULTS FROM THE RATE-RA STUDY: A MULTICENTER, OPEN-LABEL, SINGLE-ARM STUDY TO EVALUATE THE SAFETY OF ADMINISTERING RITUXIMAB AT A MORE RAPID INFUSION RATE IN PATIENTS WITH RHEUMATOID ARTHRITIS

Researchers

Presenter

  • C. H. Pritchard

Principal Investigators

  • M. W. Greenwald

  • J. M. Kremer

  • N. B. Gaylis

  • S. Zlotnick

  • C. Chung

  • B. Jaber

  • W. Reiss

Medical Centers

  • N/A

Locations

  • N/A

Companies

  • Feng Chi Biotech Cor

  • Genentech, Inc.

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Rheumatoid arthritis

  • Hypertension

  • Inflammatory Arthritis

Biomarkers

  • Circulating tumor cells

  • Tumor necrosis factor

  • Albumin/creatinine

Drug/Treatment

  • Methylprednisolone

  • Methotrexate

  • Rituximab

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved